Transplant outcomes and univariable analysis of impact of DSA desensitization at different MFI cutoffs and C1q on transplant outcomes
| . | At day 28, % . | At day 60, % . | Unadjusted SHR (95% CI) . | P value . |
|---|---|---|---|---|
| Neutrophil engraftment | ||||
| Control | 90.7 | 94.2 | Ref | Ref |
| DSA (all cases) | 75.7 | 83.8 | 0.77 (0.50-1.17) | .216 |
| DSA <10 000 MFI | 80.9 | 95.2 | 0.94 (0.59-1.52) | .813 |
| DSA 10 000-20 000 MFI | 75.0 | 75.0 | 0.67 (0.24-1.87) | .144 |
| DSA >20 000 MFI | 50.0 | 50.0 | 0.32 (0.18-1.12) | .052 |
| C1q positive | 64.3 | 88.9 | 0.50 (0.22-1.13) | .102 |
| C1q persistently positive after treatment | 50.0 | 50.0 | 0.34 (0.09-1.15) | .054 |
| C1q positive to negative after treatment | 85.7 | 85.7 | 0.87 (0.38-1.96) | .744 |
| Platelet engraftment | ||||
| Control | 45.5 | 77.2 | Ref | Ref |
| DSA | 36.0 | 58.9 | 0.65 (0.41-1.03) | .068 |
| DSA <10 000 MFI | 47.7 | 64.8 | 0.79 (0.43-1.47) | .462 |
| DSA 10 000-20000 MFI | 12.5 | 50.0 | 0.46 (0.19-1.16) | .099 |
| DSA >20 000 MFI | 16.7 | 33.3 | 0.30 (0.08-0.97) | .044 |
| C1q positive | 14.3 | 42.9 | 0.39 (0.18-0.84) | .017 |
| C1q persistently positive after treatment | 12.5 | 37.5 | 0.32 (0.11-0.97) | .045 |
| C1q positive to negative after treatment | 28.6 | 57.1 | 0.63 (0.25-1.58) | .325 |
| . | At day 28, % . | At day 60, % . | Unadjusted SHR (95% CI) . | P value . |
|---|---|---|---|---|
| Neutrophil engraftment | ||||
| Control | 90.7 | 94.2 | Ref | Ref |
| DSA (all cases) | 75.7 | 83.8 | 0.77 (0.50-1.17) | .216 |
| DSA <10 000 MFI | 80.9 | 95.2 | 0.94 (0.59-1.52) | .813 |
| DSA 10 000-20 000 MFI | 75.0 | 75.0 | 0.67 (0.24-1.87) | .144 |
| DSA >20 000 MFI | 50.0 | 50.0 | 0.32 (0.18-1.12) | .052 |
| C1q positive | 64.3 | 88.9 | 0.50 (0.22-1.13) | .102 |
| C1q persistently positive after treatment | 50.0 | 50.0 | 0.34 (0.09-1.15) | .054 |
| C1q positive to negative after treatment | 85.7 | 85.7 | 0.87 (0.38-1.96) | .744 |
| Platelet engraftment | ||||
| Control | 45.5 | 77.2 | Ref | Ref |
| DSA | 36.0 | 58.9 | 0.65 (0.41-1.03) | .068 |
| DSA <10 000 MFI | 47.7 | 64.8 | 0.79 (0.43-1.47) | .462 |
| DSA 10 000-20000 MFI | 12.5 | 50.0 | 0.46 (0.19-1.16) | .099 |
| DSA >20 000 MFI | 16.7 | 33.3 | 0.30 (0.08-0.97) | .044 |
| C1q positive | 14.3 | 42.9 | 0.39 (0.18-0.84) | .017 |
| C1q persistently positive after treatment | 12.5 | 37.5 | 0.32 (0.11-0.97) | .045 |
| C1q positive to negative after treatment | 28.6 | 57.1 | 0.63 (0.25-1.58) | .325 |
| . | At 1 y, % . | At 2 y, % . | . | . |
|---|---|---|---|---|
| NRM | ||||
| Control | 28.8 | 31.7 | Ref | Ref |
| DSA | 17.2 | 25.5 | 0.67 (0.31-1.47) | .323 |
| DSA <10 000 MFI | 15.6 | 15.6 | 0.49 (0.15-1.57) | .232 |
| DSA 10 000-20 000 MFI | 12.5 | 12.5 | 0.46 (0.06-3.81) | .475 |
| DSA >20 000 MFI | 37.5 | 58.3 | 2.18 (1.08-6.98) | .034 |
| C1q positive | 22.7 | 38.2 | 1.13 (0.40-3.20) | .815 |
| C1q persistently positive after treatment | 50 | 87.5 | 3.42 (1.30-8.90) | .013 |
| C1q positive to negative after treatment | 0 | 0 | NA | NA |
| Relapse | ||||
| Control | 22.1 | 25.8 | Ref | Ref |
| DSA | 27.8 | 41.6 | 1.41 (0.74-2.69) | .296 |
| DSA <10 000 MFI | 24.8 | 36.7 | 1.20 (0.50-2.90) | .676 |
| DSA 10 000-20 000 MFI | 38.9 | 38.9 | 1.45 (0.36-5.85) | .599 |
| DSA >20 000 MFI | 20.8 | 41.7 | 1.63 (0.42-6.40) | .479 |
| C1q positive | 29.4 | 45.6 | 1.85 (0.75-4.53) | .175 |
| C1q persistently positive after treatment | 12.5 | 12.5 | 2.68 (0.99-7.27) | .063 |
| C1q positive to negative after treatment | 40.0 | 70.0 | 0.56 (0.07-4.41) | .581 |
| . | At 1 y, % . | At 2 y, % . | . | . |
|---|---|---|---|---|
| NRM | ||||
| Control | 28.8 | 31.7 | Ref | Ref |
| DSA | 17.2 | 25.5 | 0.67 (0.31-1.47) | .323 |
| DSA <10 000 MFI | 15.6 | 15.6 | 0.49 (0.15-1.57) | .232 |
| DSA 10 000-20 000 MFI | 12.5 | 12.5 | 0.46 (0.06-3.81) | .475 |
| DSA >20 000 MFI | 37.5 | 58.3 | 2.18 (1.08-6.98) | .034 |
| C1q positive | 22.7 | 38.2 | 1.13 (0.40-3.20) | .815 |
| C1q persistently positive after treatment | 50 | 87.5 | 3.42 (1.30-8.90) | .013 |
| C1q positive to negative after treatment | 0 | 0 | NA | NA |
| Relapse | ||||
| Control | 22.1 | 25.8 | Ref | Ref |
| DSA | 27.8 | 41.6 | 1.41 (0.74-2.69) | .296 |
| DSA <10 000 MFI | 24.8 | 36.7 | 1.20 (0.50-2.90) | .676 |
| DSA 10 000-20 000 MFI | 38.9 | 38.9 | 1.45 (0.36-5.85) | .599 |
| DSA >20 000 MFI | 20.8 | 41.7 | 1.63 (0.42-6.40) | .479 |
| C1q positive | 29.4 | 45.6 | 1.85 (0.75-4.53) | .175 |
| C1q persistently positive after treatment | 12.5 | 12.5 | 2.68 (0.99-7.27) | .063 |
| C1q positive to negative after treatment | 40.0 | 70.0 | 0.56 (0.07-4.41) | .581 |
| . | At 1 y, % (95% CI) . | At 2 y, % (95% CI) . | Unadjusted HR (95% CI) . | P value . |
|---|---|---|---|---|
| OS | ||||
| Control | 57.7 (52.1-62.8) | 50.2 (44.5-55.6) | Ref | Ref |
| DSA | 68.1 (48.1-81.7) | 52.4 (26.7-72.9) | 0.89 (0.50-1.56) | .680 |
| DSA <10 000 MFI | 70.2 (41.5-86.7) | 60.1 (29.7-80.8) | 0.67 (0.30-1.53) | .352 |
| DSA 10 000-20 000 MFI | 70.0 (22.5-91.8) | 70.0 (22.5-91.8) | 0.72 (0.17-2.89) | .640 |
| DSA >20 000 MFI | 41.7 (15.6-76.7) | 20.8 (8.7-59.5) | 2.74 (1.13-4.68) | .026 |
| C1q positive | 58.4 (26.2-80.6) | 39.0 (17.8-50.5) | 1.52 (0.71-3.23) | .280 |
| C1q persistently positive after treatment | 33.3 (5.6-65.7) | 0 | 3.56 (1.57-8.09) | .002 |
| C1q positive to negative after treatment | 80.8 (30.3-96.9) | 80.8 (30.3-96.9) | 0.67 (0.17-2.72) | .578 |
| PFS | ||||
| Control | 49.1 (43.6-54.4) | 42.5 (37.0-49.0) | Ref | Ref |
| DSA | 54.9 (35.1-70.9) | 32.9 (12.7-55.0) | 1.01 (0.62-1.67) | .944 |
| DSA <10 000 MFI | 59.7 (32.2-79.3) | 47.7 (19.1-71.9) | 0.78 (0.38-1.58) | .491 |
| DSA 10 000-20 000 MFI | 48.6 (17.7-81.6) | 48.6 (17.7-81.6) | 0.89 (0.28-2.77) | .836 |
| DSA >20 000 MFI | 41.7 (15.6-56.7) | 0 | 2.49 (1.02-4.05) | .044 |
| C1q positive | 48.5 (17.8-53.8) | 16.2 (1.9-39.2) | 1.48 (0.73-3.00) | .276 |
| C1q persistently positive after treatment | 37.5 (12.8-67.4) | 0 | 2.89 (1.28-6.54) | .011 |
| C1q positive to negative after treatment | 60.0 (22.6-88.2) | 30.0 (11.2-51.9) | 0.88 (0.28-2.78) | .838 |
| . | At 1 y, % (95% CI) . | At 2 y, % (95% CI) . | Unadjusted HR (95% CI) . | P value . |
|---|---|---|---|---|
| OS | ||||
| Control | 57.7 (52.1-62.8) | 50.2 (44.5-55.6) | Ref | Ref |
| DSA | 68.1 (48.1-81.7) | 52.4 (26.7-72.9) | 0.89 (0.50-1.56) | .680 |
| DSA <10 000 MFI | 70.2 (41.5-86.7) | 60.1 (29.7-80.8) | 0.67 (0.30-1.53) | .352 |
| DSA 10 000-20 000 MFI | 70.0 (22.5-91.8) | 70.0 (22.5-91.8) | 0.72 (0.17-2.89) | .640 |
| DSA >20 000 MFI | 41.7 (15.6-76.7) | 20.8 (8.7-59.5) | 2.74 (1.13-4.68) | .026 |
| C1q positive | 58.4 (26.2-80.6) | 39.0 (17.8-50.5) | 1.52 (0.71-3.23) | .280 |
| C1q persistently positive after treatment | 33.3 (5.6-65.7) | 0 | 3.56 (1.57-8.09) | .002 |
| C1q positive to negative after treatment | 80.8 (30.3-96.9) | 80.8 (30.3-96.9) | 0.67 (0.17-2.72) | .578 |
| PFS | ||||
| Control | 49.1 (43.6-54.4) | 42.5 (37.0-49.0) | Ref | Ref |
| DSA | 54.9 (35.1-70.9) | 32.9 (12.7-55.0) | 1.01 (0.62-1.67) | .944 |
| DSA <10 000 MFI | 59.7 (32.2-79.3) | 47.7 (19.1-71.9) | 0.78 (0.38-1.58) | .491 |
| DSA 10 000-20 000 MFI | 48.6 (17.7-81.6) | 48.6 (17.7-81.6) | 0.89 (0.28-2.77) | .836 |
| DSA >20 000 MFI | 41.7 (15.6-56.7) | 0 | 2.49 (1.02-4.05) | .044 |
| C1q positive | 48.5 (17.8-53.8) | 16.2 (1.9-39.2) | 1.48 (0.73-3.00) | .276 |
| C1q persistently positive after treatment | 37.5 (12.8-67.4) | 0 | 2.89 (1.28-6.54) | .011 |
| C1q positive to negative after treatment | 60.0 (22.6-88.2) | 30.0 (11.2-51.9) | 0.88 (0.28-2.78) | .838 |
HR, hazard ratio; Ref, reference.